High demand in dermatology & wellness segments Strong repeat prescription potential Premium packaging with complete combipack convenience Ideal for hospitals, clinics & aesthetic centers Recommended Use: To be administered under medical supervision (IM/IV) as directed by a physician
These medications include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), tirzepatide (Mounjaro, Zepboundwhich also targets GIP receptors), and several others
2022 to 2023: Tirzepatide was approved for type 2 diabetes (Mounjaro) in May 2022 and for weight management (Zepbound) in November 2023
Role of oxidative stress and Nrf2/KEAP1 signaling in colorectal cancer: mechanisms and therapeutic perspectives with phytochemicals
In rare cases, serotonin syndrome